Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

ClinicalTrials.gov ID: NCT03227029

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03227029. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 when delivered as nose drops to RSV-seronegative infants 6 to 24 months of age. This study was a companion study to Center for Immunization Research (CIR) 321.

Study identification

NCT ID
NCT03227029
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Enrollment
65 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
6 Months to 24 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2017 (Actual)
Primary completion
Dec 19, 2019 (Actual)
Completion
Oct 1, 2020 (Actual)
Last update posted
Apr 22, 2022

2017 – 2020

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program La Jolla California 92093-0672 —
Usc La Nichd Crs Los Angeles California 90089 —
David Geffen School of Medicine at UCLA NICHD CRS Los Angeles California 90095-1752 —
Univ. of Colorado Denver NICHD CRS Aurora Colorado 80045 —
Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago Illinois 60612 —
Lurie Children's Hospital of Chicago (LCH) CRS Chicago Illinois 60614-3393 —
Johns Hopkins University Center for Immunization Research Baltimore Maryland 21205 —
Boston Medical Center Ped. HIV Program NICHD CRS Boston Massachusetts 02118 —
SUNY Stony Brook NICHD CRS Stony Brook New York 11794 —
Jacobi Med. Ctr. Bronx NICHD CRS The Bronx New York 10461 —
St. Jude Children's Research Hospital CRS Memphis Tennessee 38105-3678 —
Texas Children's Hospital CRS Houston Texas 77030-2399 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03227029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2022 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.